biostudies-literatureDave RVCancer Research UKMedical Research CouncilNational Institute for Health Research (NIHR)1785-1794https://www.ebi.ac.uk/biostudies/studies/S-EPMC7993073biostudies-literatureUnknown124(11)<h4>Background</h4>The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.<h4>Methods</h4>This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated 'standard' or 'COVID-altered', in the preoperative, operative and post-operative setting.<h4>Findings</h4>Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had 'COVID-altered' management. 'Bridging' endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidancBritish journal of cancerBreast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.PMC799307321133MC_U137686858CL-2017-11-002ACF-2019-21-004PB-PG-0214-33065NIHR300024Egbeare DHague MRusby JEBarry PAKrupa JKrupa KGoh NMMcCulley SJames KWilliams CSutton RJames RRutherford CLMathen VWilliams KEFerguson DTaylor AChrysafi AAbbott NRattay TKnowles HRobb HDNasir NGandamihardja TForouhi PHargreaves ACarmichael AJacklin RAinsworth RRayter ZYoung IFafemi OHawkins SYoussef MMGMullan MUrquhart GAbdalla ERJain UKaragiannidis GZechmeister KGathani TBezzaa SKattakayam AAllum WHGarreffa EHill ADKPoonawala STaxiarchi VPPotter SGirgis MMassey JSomasundaram SDouek MIsgar BGvaramadze ACheung KLAl-Mufti RTanhueco ARana DSAthanasiou IKirkham JJTurner JCariati MCain HKirwan CCGowda MStallard SDodwell DRoy PMirshekar-Syahkal BRoche NAdwani APereira BColes CEPeck JSalvador ROlsen SDrew PSalih APogson CHorne SQuinn EKalra LLafi MLiptay-Wagner PRasheed TSahu ARapisarda FBramley MMatey PTansley ASarakbi WAMortimer CBetambeau NStanilov NB-MaP-C study collaborativeVerroiotou MKothari AWignarajah PPhyu SHMehta DKhan LRCritchley AKirkpatrick KAchuthan RGill JLaban CCharalampoudis PAnsari ABenson JHadjiminas DSharma AKantola VVidya RParmeshwar RChagla LHurley ARSarker MSotheran WMallidis ELai LMElahi MBHussien MChatterjee SKaushik MGui GSharma NZammit CTaraki ZMcManus PPrusty LBarnes NNajeeb EChandrashekar MLobo CCallaghan MCutress RISharif MAMckenzie SDunn JJones LNoronha JLHollywood CAlkistawi FEBJenkins SCBosch KRobertson SChaudhry AHarborough KEMarsh SDoughty JLee RXNAllen MJJohnson RWallace SMylvaganam SDash IShokuhi SDani MBathla SSakellariou VMurphy JAbbas AChandrasekharan SMacinnes EWilliams-Jones SSmyth EOoi JAbbas IFairbrother PPieri AWhitehead IBakri NACAlder LShrotri AMallon PSein TACamacho EMKalakouti EWhisker LRalph JIrvine TFranks JWardle SPartlett PIrwin GWRowland MDimopoulos NBentley JWaheed SGandhi AOdofin OShaheed SChalmers RSami AElfadl DSulieman MHamed HHolcombe CNtakomyti EMonib SWalsh AMartin LSatpathy AMoody AWilliams SKElsberger BRay ABoundouki GRew DBanks JElamass MMerker LScally NSait MRChong KAl-Zawi ASAMcEvoy KJafferbhoy SThiruchelvam PHogan BCook LVashisht RBichoo RAPeerlink IHenderson JMcIntosh SAByrne GCook JGovindarajulu SCopson ERemoundos DThekkinkattil DCourtney AHardy RDavies EHorgan KBunza RRomics LAmin KThorne AMacLean GAbsar MKim BDent HSweetland HMHarries STurton PMazari FAkolekar DBurrah RSoulsby RFairhurst KThomas RKallaway CSasi WSircar THogben KThomson SSousa EBonomi RIves CCartlidge CWJMondani GKnight AGoyal ALaw RVinayagam RLaurence NKenny FBarkeji MAgrawal ATabbakh RVatish JZeidan BPatani NAitken JSaha SWilson CCox KSoumian SHighton LBarua EAzmy IMitchell GOni GMcIntosh JLambert KDaltrey IDave RVMullen RChopra SBrown ILeff DRGahir JGallegos NHamad AAthwal RShin HMathers HGoyal SSegaran AMarla Sde Silva TSHeeney ABarker SEnglish REO'Connell RWahedna YExarchos GMikhael YPain SAl-Ishaq ZBatt JHarding-Mackean CKhalifa EKhout HMacmillan RImran ACuffolo GKrzyzanowska CRathinaezhil RMcGoldrick CEid RHarvey JMasannat YSalman RElkorety MPodesta CSalman MFatayer HSalem FSuleiman UKiernan TBetal DChambers AAsgeirsson KCourtney CAGopalan VJibril JNair RValassiadou KDumitru DPower CShere MTouqan NKing PAgabiti EBanerjee DMaalo JNavin CSibbering DMRavichandran DNoor LPakzad FLund JJoshi SRamzi SSloan SASardar MVClayton ETillett RNarayanan SSeward JClayton GDevalia HChouhan ATuffaha HSimonca CHorsnell JDFuller MCoombs NSmith SDua SPilgrm SSt John ERCfalseBreast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.<h4>Background</h4>The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.<h4>Methods</h4>This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated 'standard' or 'COVID-altered', in the preoperative, operative and post-operative setting.<h4>Findings</h4>Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had 'COVID-altered' management. 'Bridging' endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidanc2021-01-01T00:00:00Z2021 May2025-04-21T19:37:23.918Z2022-02-11T01:28:41.65ZS-EPMC79930733376742210.1038/s41416-020-01234-4